Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0921803.3Aexternal-prioritypatent/GB0921803D0/en
Application filed by Biocopea LtdfiledCriticalBiocopea Ltd
Publication of ECSP12011969ApublicationCriticalpatent/ECSP12011969A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Un agente comprende teobromina y una antihistamina, como una preparación combinada para el uso simultáneo, secuencial o por separado en terapia, específicamente en la terapia para la tos.An agent comprises theobromine and an antihistamine, as a combined preparation for simultaneous, sequential or separate use in therapy, specifically in cough therapy.
ECSP120119692009-12-142012-06-12
THERAPEUTIC COMBINATIONS OF THEOBROMINE AND AN ANTIHISTAMINE
ECSP12011969A
(en)
Pharmaceutical combinations comprising a b-raf inhibitor, an epidermal growth factor receptor inhibitor and optionally a pi3halpha inhibitor and use in the treatment of a proliferative disease.
combination of (a) an immunoconjugate, pharmaceutical composition, use of (a) an immunoconjugate, method of treating a disease in an individual, method of stimulating cellular function in an individual, and kit for treating a disease.
An inclusion complex comprising a) a cyclodextrin, b) fulvestrant and c) a carrier; its method of preparation; formulation and dosage form comprising the complex; preparation comprising the complex or formulation; and its use in the treatment of cancer and systemic lupus erythematosus, among other diseases.
A combination containing 2-amino-n- [7-methoxy-8- (3-morpholin-4-ylpropoxy) -2,3-dihydroimidazo [1,2-c] quinazolin-5-yl] pyrimidin-5-carboxamide and abt-737; and its use for the treatment or prophylaxis of breast cancer, in particular inflammatory breast cancer, triple negative breast cancer, her2 receptor positive breast cancer and hormone receptor positive breast cancer.
PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ASSOCIATION OF I) CYCLLOBENZAPRINE, II) ACECLOFENACO AND OPTIONALLY III) EXCIPIENTS; AND ITS USE FOR THE TREATMENT OF PAINFUL MUSCLE DISEASES.
Using pirfenidone to treat a patient in need of it comprising avoiding or discontinuing the concomitant use or co-administration of a strong cyp1a2 inducer to avoid reduced exposure to pirfenidone.